reduce side effects of semaglutide GLP-1 and Semaglutide: Why Smart Biomarker Monitoring Matters Semaglutide: Double-edged Sword with Risks

In April and December of 2022, respectively, the FDA determined that semaglutide and tirzepatide were in short supply, opening the floodgates for compounding pharmacies and outsourcing facilities to manufacture, distribute and market copies, typically sold through telehealth companies, medical spas and wellness centers

The detection limit was 1.7 micrograms per liter, and every single sample came back below that threshold

A slightly higher number of hospitalizations occurred with semaglutide, but serious adverse event rates were similar to placebo

Jiaming Y, Rahimi MH

Constipation GLP-1 medications slow gastric emptying, which can lead to constipation

It can assist in precise cancer diagnosis, targeted drug delivery, and improved therapeutic efficacy [108, 109]